It was found that STX6 expression was linked to various immunological pathways, including TNFA signaling via NFKB, IFN-α, IFN-β, and inflammation, as well as allograft-rejection pathways in kidney cancer (KICH, KIRC, and KIRP), CESC, and PAAD; however, this was not the case for other cancers, including LGG, MESO, OV, SARC, SKCM, and STAD (Figure 3). Here, STX6 is linked to pancreatic adenocarcinoma.